Identification of RSPO2 Fusion Mutations and Target Therapy Using a Porcupine Inhibitor

Cancers are driven by a variety of somatic gene mutations and identifying these mutations enables the development of novel target drugs. We have sought to identify abnormalities in Wnt pathway-related genes that are sensitive to Wnt inhibitor treatment. We examined Patient Derived Xenograft (PDX) RN...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Chong, Cao, Jing, Zhang, Ning, Tu, Meiqing, Xu, Fengwei, Wei, Shuang, Chen, Xiaojing, Xu, Yuhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6155119/
https://www.ncbi.nlm.nih.gov/pubmed/30250044
http://dx.doi.org/10.1038/s41598-018-32652-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6155119/
https://www.ncbi.nlm.nih.gov/pubmed/30250044
http://dx.doi.org/10.1038/s41598-018-32652-3

Ejemplares similares